Thursday, February 08, 2007

National Television Series, Business & Beyond, to Feature Nutra Pharma on CNBC

BOCA RATON, Fla.--(BUSINESS WIRE)--Feb 8, 2007 - Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has today announced that it has been selected by Platinum Television Group to be featured on the national television series "Business & Beyond."

"The opportunity to be featured on this television series is timely, as we recently announced that our drug discovery division, ReceptoPharm, had commenced its Phase IIb human clinical trial for the treatment of Adrenomyeloneuropathy (AMN)," commented Rik J. Deitsch, Chairman and CEO of Nutra Pharma Corporation. "Being featured on 'Business & Beyond' will provide Nutra Pharma with a large national audience, with whom we can discuss our recent accomplishments and explain our business model," he added.

The segment, entitled "Bringing Bio-Technologies to Market," will be featured on CNBC, with repeat airings occurring 100 times in 25 leading markets across the United States over the next several months. Filming was recently completed and the segment is now completing post-production.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The feature of Nutra Pharma on "Business & Beyond" should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


Nutra Pharma Corp.
David Isserman (Investor Relations), 877-895-5647